Literature DB >> 33916264

Triple-Drug Treatment Is Effective for Lymphatic Filariasis Microfilaria Clearance in Samoa.

Patricia M Graves1, Sarah Sheridan2, Jessica Scott1, Filipina Amosa-Lei Sam3, Take Naseri4, Robert Thomsen4, Christopher L King5, Colleen L Lau6,7.   

Abstract

Following the first triple-drug mass drug administration (MDA) for lymphatic filariasis in Samoa in 2018, unexpected persistence of microfilaria (Mf) positivity in 18 (15%) of 121 antigen-positive persons was observed in a nationwide household survey 1-2 months later. Of the 18 Mf positive persons, 14 reported taking the MDA, raising concerns about MDA efficacy. In 2019, 5-6 months after the 2018 survey, a monitored treatment study was done to evaluate directly observed weight-based treatment in these Mf positive individuals. Mf presence and density were assessed before and 7 days after treatment, using 1 mL membrane filtered venous blood, and 60 uL thick blood films on slides prepared from venous or fingerprick blood. All 14 participants were still Mf positive on filters from venous blood pre-treatment samples, but two were negative by slide made from the same samples. Mf were cleared completely by day 7 in 12 of 13 participants followed up, and by day 30 in the remaining participant. Filtered blood using EDTA samples (to reduce clumping of Mf) is preferred over slides alone for improving the likelihood of detecting Mf and estimating their density. The triple-drug MDA strategy was effective at clearing Mf when given and taken at the correct dose.

Entities:  

Keywords:  DEC; Samoa; albendazole; ivermectin; lymphatic filariasis; microfilaria

Year:  2021        PMID: 33916264     DOI: 10.3390/tropicalmed6020044

Source DB:  PubMed          Journal:  Trop Med Infect Dis        ISSN: 2414-6366


  23 in total

1.  Observations of agglutination and thigmotaxis of microfilariae in bancroftian filariasis.

Authors:  M YOELI
Journal:  Trans R Soc Trop Med Hyg       Date:  1957-03       Impact factor: 2.184

2.  A technique for microfilarial detection in preserved blood using nuclepore filters.

Authors:  J W Dickerson; M L Eberhard; P J Lammie
Journal:  J Parasitol       Date:  1990-12       Impact factor: 1.276

3.  Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis.

Authors:  Edward K Thomsen; Nelly Sanuku; Manasseh Baea; Samson Satofan; Elit Maki; Bart Lombore; Mark S Schmidt; Peter M Siba; Gary J Weil; James W Kazura; Lawrence L Fleckenstein; Christopher L King
Journal:  Clin Infect Dis       Date:  2015-10-20       Impact factor: 9.079

4.  Studies of filariasis in the Pacific. 2. The persistence of microfilaraemia in diethylcarbamazine treated populations of Fiji and Western Samoa: diagnostic application of the membrane-filtration technique.

Authors:  R S Desowitz; B A Southgate
Journal:  Southeast Asian J Trop Med Public Health       Date:  1973-06       Impact factor: 0.267

5.  Bancroftian filariasis in an isolated hunter-gatherer shifting horticulturist group in Papua New Guinea.

Authors:  R S Desowitz; C Jenkins; G Anian
Journal:  Bull World Health Organ       Date:  1993       Impact factor: 9.408

6.  Seroprevalence and spatial epidemiology of Lymphatic Filariasis in American Samoa after successful mass drug administration.

Authors:  Colleen L Lau; Kimberly Y Won; Luke Becker; Ricardo J Soares Magalhaes; Saipale Fuimaono; Wayne Melrose; Patrick J Lammie; Patricia M Graves
Journal:  PLoS Negl Trop Dis       Date:  2014-11-13

Review 7.  Setting the stage for a Global Programme to Eliminate Lymphatic Filariasis: the first 125 years (1875-2000).

Authors:  Eric A Ottesen; John Horton
Journal:  Int Health       Date:  2020-12-22       Impact factor: 2.473

Review 8.  Progress in the elimination of lymphatic filariasis in the Western Pacific Region: successes and challenges.

Authors:  Aya Yajima; Kazuyo Ichimori
Journal:  Int Health       Date:  2020-12-22       Impact factor: 2.473

9.  Two decades of public health achievements in lymphatic filariasis (2000-2020): reflections, progress and future challenges.

Authors:  Mwelecele Malecela; John Gyapong; K D Ramaiah; David Molyneux
Journal:  Int Health       Date:  2020-12-22       Impact factor: 2.473

10.  Identifying residual transmission of lymphatic filariasis after mass drug administration: Comparing school-based versus community-based surveillance - American Samoa, 2016.

Authors:  Meru Sheel; Sarah Sheridan; Katherine Gass; Kimberly Won; Saipale Fuimaono; Martyn Kirk; Amor Gonzales; Shannon M Hedtke; Patricia M Graves; Colleen L Lau
Journal:  PLoS Negl Trop Dis       Date:  2018-07-16
View more
  1 in total

1.  The Importance of Partnership in the Rollout of Triple-Drug Therapy to Eliminate Lymphatic Filariasis in the Pacific.

Authors:  Merelesita Rainima-Qaniuci; Hansell Blanche Lepaitai; Rasul Bhagirov; Eswara Padmasiri; Take Naseri; Robert Thomsen; Kimberly Y Won; Tara A Brant; Emily Dodd; Motusa Tuileama Nua; Fara Utu; Aifili Tufa; Emi Chutaro; Janet Camacho; Lynette Suiaunoa-Scanlan; Li Jun Thean; Jyotishna Mani; Myra Hardy; Josaia Samuela; Lucia Romani; John Kaldor; Andrew C Steer; Daniel Faktaufon; Vinaisi Bechu; Flora Naqio; Vine Sosene; Makoto Sekihara; Junko Otaki; Tamara S Buhagiar; Aya Yajima
Journal:  Am J Trop Med Hyg       Date:  2022-03-15       Impact factor: 3.707

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.